Advertisement

 

 

A randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.

A randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Author Information (click to view)

Inoue T, Nishimura A, Sasai K, Kitagawa T,


Inoue T, Nishimura A, Sasai K, Kitagawa T, (click to view)

Inoue T, Nishimura A, Sasai K, Kitagawa T,

Advertisement

Psychiatry and clinical neurosciences 2017 11 21() doi 10.1111/pcn.12623
Abstract
AIM
Safety and efficacy of vortioxetine (5-20 mg/day) in Japanese patients with major depressive disorder were evaluated in two phase 3 studies consisting of a short-term, 8-week, placebo-controlled, double-blind study followed by a long-term, 52-week, open-label extension study.

METHODS
The primary endpoint of the short-term study was change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 8. The primary objective of the extension study was vortioxetine’s long-term safety; efficacy endpoints included change in MADRS total score, clinical global impression scale-severity (CGI-S) score from the long-term study baseline, and clinical global impression scale-improvement (CGI-I) score over 52 weeks.

RESULTS
Of the 366 randomized patients, 338 completed the short-term study, and 119 patients continued into the extension study. Primary (analysis of covariance [ANCOVA]) and secondary (mixed model for repeated measurements [MMRM]) analyses in the short-term study showed numerically greater, but not statistically significant, decreases in change in MADRS total score from baseline between vortioxetine and placebo groups at week 8. In the long-term study, 86.6% of patients reported at least 1 treatment-emergent adverse event (TEAE), with most common being nasopharyngitis (40.3%) and nausea (21%). MADRS total score and CGI-I and CGI-S scores improved with continued vortioxetine treatment from baseline of the open-label study to week 52.

CONCLUSIONS
Vortioxetine failed to meet significance versus placebo in the primary efficacy analysis at week 8 in the short term-study. The extension trial indicated continued improvement of depressive symptoms from baseline of this study throughout the 52-week treatment period. Vortioxetine treatment was safe and well tolerated in both studies.

TRIAL REGISTRATION
The short-term study has the ClinicalTrials.gov identifier NCT01355081; the open-label, long-term extension trial has the ClinicalTrials.gov identifier NCT01395147.

Submit a Comment

Your email address will not be published. Required fields are marked *

16 − four =

[ HIDE/SHOW ]